Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

Por Kavanaugh, A, Krueger, G G, Beutler, A, Guzzo, C, Zhou, B, Dooley, L T, Mease, P J, Gladman, D D, de Vlam, K, Geusens, P P, Birbara, C, Halter, D G, Antoni, C
Publicado em 2007